Focus: Tempus is an AI-driven biotech company focused on drug discovery and medical devices across oncology, gastroenterology, ophthalmology, neurology, and cardiovascular indications. The company operates as a mid-stage biotech leveraging machine learning platforms to accelerate development timelines.
Profile data last refreshed 14h ago · AI intelligence enriched 1w ago
Hot — 69 jobs added in 30d
Net +26 (69 new, 43 removed). Aggressive expansion phase.
Best suited for data scientists, AI engineers, and real-world evidence professionals seeking to build emerging precision medicine infrastructure; less ideal for those prioritizing traditional drug development or near-term clinical validation.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Tempus
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Tempus's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Tempus AI: AI Precision Medicine With A Moat (NASDAQ:TEM) - Seeking Alpha
Tempus AI: AI Precision Medicine With A Moat (NASDAQ:TEM) Seeking Alpha
FDA Approves Tempus AI Tumor-Only Sequencing Platform - HarianBasis.co
FDA Approves Tempus AI Tumor-Only Sequencing Platform HarianBasis.co
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development - Business Wire
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development Business Wire
Tempus AI Stock Climbs As Pharma, Alzheimer’s Deals Build Momentum - timothysykes.com
Tempus AI Stock Climbs As Pharma, Alzheimer’s Deals Build Momentum timothysykes.com
Tempus AI And BMS Deepen AI Drug Development Ties As Losses Persist - Yahoo Finance
Tempus AI And BMS Deepen AI Drug Development Ties As Losses Persist Yahoo Finance
BMS teams up with Tempus to see if AI can improve clinical success - FirstWord Pharma
BMS teams up with Tempus to see if AI can improve clinical success FirstWord Pharma
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo